{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:30:32Z","timestamp":1789644632238,"version":"4.0.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T00:00:00Z","timestamp":1443052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00277-015-2489-6","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T19:28:09Z","timestamp":1443036489000},"page":"2003-2013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)"],"prefix":"10.1007","volume":"94","author":[{"given":"Heiko","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Suciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn Hans","family":"R\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristoteles","family":"Giagounidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Selleslag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Labar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Muus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Pfl\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hagemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Eckart","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Fiaccadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Aul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre W.","family":"Wijermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,24]]},"reference":[{"key":"2489_CR1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079\u20132088","journal-title":"Blood"},{"key":"2489_CR2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0145-2126(00)00088-6","volume":"24","author":"U Germing","year":"2000","unstructured":"Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983\u2013992","journal-title":"Leuk Res"},{"key":"2489_CR3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/cncr.21699","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Beran M, Cortes J et al (2006) Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 106:1099\u20131109","journal-title":"Cancer"},{"key":"2489_CR4","first-page":"1513","volume":"91","author":"B Deschler","year":"2006","unstructured":"Deschler B, de Witte T, Mertelsmann R, L\u00fcbbert M (2006) Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 91:1513\u20131522","journal-title":"Haematologica"},{"key":"2489_CR5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/leu.2013.173","volume":"27","author":"EH Estey","year":"2013","unstructured":"Estey EH (2013) Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 27:1803\u20131812","journal-title":"Leukemia"},{"key":"2489_CR6","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Mufti GJ, Hellstr\u00f6m-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low BM blast count acute myeloid leukemia. J Clin Oncol 28:562\u2013569","journal-title":"J Clin Oncol"},{"key":"2489_CR7","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670\u20132677","journal-title":"J Clin Oncol"},{"key":"2489_CR8","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M, Suciu S, Baila L et al (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29:1987\u20131996","journal-title":"J Clin Oncol"},{"key":"2489_CR9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189\u2013199","journal-title":"Br J Haematol"},{"key":"2489_CR10","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H et al (2000) World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671\u20133674","journal-title":"Blood"},{"key":"2489_CR11","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The survival analysis of failure time data","author":"JD Kalbfleisch","year":"2002","unstructured":"Kalbfleisch JD, Prentice RL (2002) The survival analysis of failure time data, 3rd edn. Wiley Inter-Science, Hoboken","edition":"3"},{"key":"2489_CR12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71\u201385","journal-title":"Lancet"},{"key":"2489_CR13","first-page":"18","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"JW Vardiman","year":"2008","unstructured":"Vardiman JW, Brunning RD, Arber DA et al (2008) Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 18\u201330","edition":"4"},{"key":"2489_CR14","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","volume":"24","author":"LR Silverman","year":"2006","unstructured":"Silverman LR, McKenzie DR, Peterson BL et al (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895\u20133903","journal-title":"J Clin Oncol"},{"key":"2489_CR15","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794\u20131803","journal-title":"Cancer"},{"key":"2489_CR16","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","volume":"27","author":"DP Steensma","year":"2009","unstructured":"Steensma DP, Baer MR, Slack JL et al (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27:3842\u20133848","journal-title":"J Clin Oncol"},{"key":"2489_CR17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clml.2013.05.004","volume":"13","author":"E Jabbour","year":"2013","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S et al (2013) Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk 13:592\u2013596","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2489_CR18","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","volume":"120","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Ravandi F, Liu-Dumlao T et al (2012) Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 120:4840\u20134845","journal-title":"Blood"},{"key":"2489_CR19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.12256","volume":"161","author":"YG Lee","year":"2013","unstructured":"Lee YG, Kim I, Yoon SS et al (2013) Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol 161:339\u2013347","journal-title":"Br J Haematol"},{"key":"2489_CR20","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00277-013-1702-8","volume":"92","author":"JH Lee","year":"2013","unstructured":"Lee JH, Choi Y, Kim SD et al (2013) Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome. Ann Hematol 92:889\u2013897","journal-title":"Ann Hematol"},{"key":"2489_CR21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-3-10","volume":"3","author":"BD Smith","year":"2014","unstructured":"Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ (2014) Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol 3:10","journal-title":"Exp Hematol Oncol"},{"key":"2489_CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clml.2014.04.010","volume":"15","author":"M Xie","year":"2015","unstructured":"Xie M, Jiang Q, Xie Y (2015) Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Clin Lymphoma Myeloma Leuk 15:22\u201328","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2489_CR23","first-page":"124","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"DA Arber","year":"2008","unstructured":"Arber DA, Brunning RD, Orazi A et al (2008) Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 124\u2013126","edition":"4"},{"key":"2489_CR24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:291\u2013299","journal-title":"Blood"},{"key":"2489_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","volume":"28","author":"L Shen","year":"2010","unstructured":"Shen L, Kantarjian H, Guo Y et al (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605\u2013613","journal-title":"J Clin Oncol"},{"key":"2489_CR26","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","volume":"107","author":"W Blum","year":"2010","unstructured":"Blum W, Garzon R, Klisovic RB et al (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 107:7473\u20137478","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2489_CR27","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/leu.2011.342","volume":"26","author":"KH Metzeler","year":"2012","unstructured":"Metzeler KH, Walker A, Geyer S et al (2012) DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 26:1106\u20131107","journal-title":"Leukemia"},{"key":"2489_CR28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","volume":"97","author":"M L\u00fcbbert","year":"2012","unstructured":"L\u00fcbbert M, R\u00fcter BH, Claus R et al (2012) A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 97:393\u2013401","journal-title":"Haematologica"},{"key":"2489_CR29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00277-012-1595-y","volume":"92","author":"H Wang","year":"2013","unstructured":"Wang H, Fan R, Wang XQ et al (2013) Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome. Ann Hematol 92:199\u2013209","journal-title":"Ann Hematol"},{"key":"2489_CR30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-012-1635-7","volume":"92","author":"JH Yi","year":"2013","unstructured":"Yi JH, Huh J, Kim HJ et al (2013) Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. Ann Hematol 92:459\u2013469","journal-title":"Ann Hematol"},{"key":"2489_CR31","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3324\/haematol.2013.101386","volume":"99","author":"H Yun","year":"2014","unstructured":"Yun H, Damm F, Yap D et al (2014) Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica 99:1456\u20131464","journal-title":"Haematologica"},{"key":"2489_CR32","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K et al (2014) TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124:2705\u20132712","journal-title":"Blood"},{"key":"2489_CR33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.leu.2400550","volume":"11","author":"RL Momparler","year":"1997","unstructured":"Momparler RL, C\u00f4t\u00e9 S, Eliopoulos N (1997) Pharmacological approach for optimization of the dose schedule of 5-aza-2\u2019-deoxycytidine (decitabine) for the therapy of leukemia. Leukemia 11:175\u2013180","journal-title":"Leukemia"},{"key":"2489_CR34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.leukres.2015.03.006","volume":"39","author":"M Cabrero","year":"2015","unstructured":"Cabrero M, Jabbour E, Ravandi F et al (2015) Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res 39:520\u2013524","journal-title":"Leuk Res"},{"key":"2489_CR35","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","volume":"116","author":"M Lima de","year":"2010","unstructured":"de Lima M, Giralt S, Thall PF et al (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116:5420\u20135431","journal-title":"Cancer"},{"key":"2489_CR36","doi-asserted-by":"crossref","unstructured":"Pusic I, Choi J, Fiala MA et al (2015) Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Transplant 21:1761\u20131769","DOI":"10.1016\/j.bbmt.2015.05.026"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2489-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2489-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T13:23:12Z","timestamp":1599571392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2489-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,24]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2489"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2489-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,24]]}}}